Clinical stage biopharmaceutical company Carisma Therapeutics Inc on Tuesday announced an expansion of its in vivo CAR-M collaboration with Moderna Inc (Nasdaq:MRNA) to include the development of two therapies for autoimmune diseases.

Building on their successful pre-clinical work in oncology, the companies will leverage their respective technologies to develop novel in vivo macrophage engineering approaches for two nominated autoimmune disease targets.

Carisma will receive research funding and milestone payments, as well as royalties on any commercialised products.